Next Phase Newsletter

A life sciences investment firm has a global diversified strategy ranging from seed stage to public companies, and including innovation, restructuring opportunities, and growth investing. The firm’s investment team brings a wealth of experience across all areas of the life sciences industry. Nearly all of the firm’s partners have been with the firm for 12 years or more, and they are supported by over 20 investment professionals, distinguished advisers, and scientific advisory board members. The firm has no set number of allocations that it plans to make, but is actively reviewing new opportunities from around the globe. The firm has a history of strategic relationships with other venture capital firms or funds targeting specific sectors or geographies within the life sciences.  These working relationships help give the firm a global footprint and vastly expand their deal flow. 
 
The firm’s general life sciences funds represent approximately $1.3 billion in capital commitments. These funds target a diverse group of life sciences companies, across all stages of development. The firm’s funds have invested in over 100 portfolio companies covering a broad range of life science sectors, including biopharmaceuticals, drug discovery and research tools, medical devices, diagnostics, digital health, nutrition, and agribusiness. 
 
The firm seeks to invest its capital in life sciences companies where our operational, financial, and scientific expertise can assist management in building companies. This investment approach has remained largely consistent since 1997, delivering attractive returns to their investors. Effective management is critical to the success of our portfolio companies. The firm assists their portfolio companies in recruiting and retaining key management and advisors, identifying product opportunities, establishing and negotiating strategic partnerships, and providing assistance with product development and execution. The firm develops close working relationships with our management teams to establish ourselves as true partners in business building. The firm strongly prefers board representation, and have received a board seat with 90% of their portfolio companies (based on invested capital). The firm believes this commitment of intellectual capital increases the likelihood of positive outcomes for our investments, and has established them as a preferred partner in the industry. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

A venture capital firm makes around 1/3 of its investments in industry tech mainly focusing on digital transformation within traditional sectors, second 1/3 in enterprise tech including both SaaS and network technology, and the last 1/3 in healthcare, including AI in healthcare and medical devices. The firm manages 3 funds right now, and the latest fund closed in 2022. The firm typically invests $1M-$2M initial check per company,  and reserve 2/3 of the fund for pro rata. The firm prefers to lead the round and also open to co-investment. The firm typically makes 7-10 new investments per year, and only focuses on companies based in North America (USA & Canada). Furthermore, the firm has a considerable value-add in supporting companies leveraging their former entrepreneur and operator experience, and their CXO network which includes over 30 executives from Fortune 1000 companies. 
 
The firm is open to all subsectors of AI in healthcare, diagnostics and all classes of medical devices. The firm is indication agnostic and looks primarily at early-stage companies, particularly at the seed pre-Series A stage. 
 
The firm does not have a particular management team requirement, as it primarily assesses the technology itself. If leading the round, the firm will take a board seat after an investment. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

A leading alternative asset manager in Europe – investing in early-stage VC, growth VC, venture debt, strategic equity in listed companies, infrastructure and private equity – providing financing solutions to companies throughout their life-cycle. Founded in 2008, the firm counts on 210 active companies, 64 exits and more than €1,2bn of assets under management. Some of the firm’s portfolio companies have been acquired by multinationals such as Intel, Symantec, IBM, and Facebook, whilst others are listed in public markets such as NASDAQ, the Spanish BME Growth, AIM London, and Euronext Growth. 
 
In the life sciences, the firm focuses on therapeutics and also CDMOs, medical devices, healthcare and Digital Health. In therapeutics, the firm focuses on preclinical opportunities with a focus on assets that are 12-18 months prior to IND. The firm generally does not invest in large indication areas such as diabetes, metabolic disease, cardiovascular and renal disease. Outside of Therapeutics, the firm invests in companies that are revenue positive. Ticket sizes range from 1-5M€. 
 
In therapeutic opportunities, the firm seeks companies that have obtained proof of concept data in animal studies and can reach human clinical trials with financial needs of up to EUR 15million to reach a human Proof of Efficacy. In Spain, the firm typically leads investment rounds, and may syndicate with other firms or leverage public funding. Outside of Spain, the firm seeks to co-invest in rounds led by local top-tier Venture Capital. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

A venture capital firm is part of a large investment holding company with over €25 billion in assets under management. The firm actively seeks early-stage investment opportunities in global companies that offer disruptive therapeutic approaches across modalities and disease areas, specifically addressing unmet medical needs. The firm offers evergreen support until key value-added milestones and meaningful impact are achieved. Investment sizes typically range from 1 to 10 million euros, with the capacity for larger follow-on investments in portfolio companies. The firm is open to participation at any stage, with a preference for Seed to Series B rounds. The firm’s willingness to lead or co-invest extends to companies in Spain and Portugal, and the firm also participates as a co-investor globally, with a special focus on the EU.

The firm is a flexible and opportunistic investor that is currently considering disruptive therapeutics companies in areas of unmet need. The firm will look at opportunities of all stages from pre-clinical to phase I/II.

The firm will invest in privately held companies only. The firm seeks companies with a full-time management team with expertise, successful track records would be a plus but is not required. The firm takes a board seat in portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

A private equity fund in China mainly focuses pharmaceuticals, medical device & diagnostic, and healthcare services. The firm typically makes equity investments of US$5-10 million per deal over a 5-6 year exit horizon. The firm is open to leading or co-investing. The firm is investing from its RMB and USD funds and is currently seeking opportunities from China and the U.S.

The firm has a clearly defined investment focus primarily on three healthcare subsectors: Pharmaceuticals, Medical Device & Diagnostic, and Medical Service. Within pharmaceuticals, the firm considers chemical drugs in Oncology, Cardiovascular, Gastrointestinal, second generation drugs, brand generics, OTC, drug delivery platforms, CRO/CMO; biotech products in Biosimilar, Vaccines, blood product, etc.; and Traditional Chinese Medicine (TCM). The firm prefers first-in-class projects in phase I or IIa with safety and efficacy data. Within Medical Device and Diagnostics, the firm is interested in High-end devices, Consumables, Implantable Devices and Interventional Devices with high-technical barrier, Molecular Diagnostics, Immunological Diagnostics, and Genetic Diagnostics. The firm is especially interested in medical robotics and AI. In addition, the firm would consider R&D services that support cell therapy, stem cell, and new therapies. For 505b2 drugs or medical devices, the firm considers from preclinical to pre-IND stages.

The firm is looking for experienced management teams with sector expertise. Within China, the firm prefers companies with approved products and sales track record. Within the U.S., the firm can consider earlier stage companies depending on the business model and exit strategy. The firm’s GP has a strong network in China and can offer assistance in distribution and registration. For therapeutics, the firm prefers companies who have completed Phase 1 and Phase 2a trials and can show some safety and efficacy data.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

A corporate venture arm of a large, diversified business headquartered in Asia, focuses on investing in healthcare among other business areas.

The team has offices in USA, Western Europe, and Germany. The fund has an evergreen structure looking to allocate between $1-$3 million per deal initially and up to $5 million over the life of the investment. They are seeking to invest in approximately 2-4 companies over the next 12 months and are open to investing in companies across the globe.

Sectors of interest include: pharmaceuticals, medical device and digital health. Therapeutic and product areas of interest include: Pain, critical care, musculoskeletal disease, kidney disease, DDS, patient monitoring technologies, bioprocessing technologies, digital therapeutics. The firm is open to all stages of investment, with a general preference toward companies with at least some early clinical data.

The firm invests in private companies and is willing to work with all types of management teams including incomplete teams. The firm generally requests at least an observer seat following investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

A venture capital company with offices in the US is looking to make equity investments that can range from approx. $2-$15M depending on the opportunity. The firm is comfortable acting as both a lead or co-investor. The firm looks for companies primarily in the United States and will also consider companies from Europe and Canada.

The firm is primarily interested in sectors of therapeutics, life science tools, and digital health. In the Therapeutics space the firm is looking for both small molecule and biologics companies and is open to both platform and single asset companies. The firm is generally open to all indications but has significant expertise in the CNS space. Due to the firms two funds they are able and interested in investing in companies with products across the development cycle from preclinical – Phase III.

The firm is comfortable working with incomplete management teams and has assisted in hiring executive for portfolio companies in the past. The firm almost always look to take a board seat following investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.